Product Categories
| Country: | China |
|---|---|
| Tel: | |
| Mobile: | +8615002134094 |
| E-mail: | marketing@targetmol.cn |
| QQ: | 2881954871 |
| Skype: | Chat Now! |
| Product Name | MF | CAS | Details |
|---|
| NSC243928 mesylate | C22H21N3O3S.CH4O3S | 59988-01-1 | Details |
| CYP4A11/CYP4F2-IN-1 | C15H15N3OS | 502654-40-2 | Details |
| PARP1/2/TNKS1/2-IN-1 | C35H31FN6O5 | 2243453-32-7 | Details |
| R 59-022 hydrochloride | C27H27ClFN3OS | 93076-98-3 | Details |
| Dazostinag disodium | C21H23F2N8NaO10P2S2 | 2553413-93-5 | Details |
| Nampt activator-2 | C17H15ClN4O3S | 2237268-90-3 | Details |
| Ebaresdax hydrochloride | C12H15ClN2O3S | 1334385-87-3 | Details |
| PARP-2-IN-3 | C20H20ClN3O3 | 2915650-86-9 | Details |
| OTUB1/USP8-IN-1 | C22H16ClFN2O4 | 2858800-98-1 | Details |
| (Rac)-SHIN2 | C23H26N4O3 | 2204289-53-0 | Details |
| APOBEC3G-IN-1 | C15H11NO3 | 14261-92-8 | Details |
| SID-852843 | C17H15N3O5S | 909859-19-4 | Details |
| CYP1B1-IN-5 | C14H8INO2 | 176442-56-1 | Details |
| JNJ-49095397 | C34H36N6O4 | 1220626-82-3 | Details |
| Moiramide B | C25H31N3O5 | 155233-31-1 | Details |
| Angiotensin 1/2 (1-9) TFA | Details |
| MitoSOX Red | C43H43IN3P | 1003197-00-9 | Details |
| SOS1-IN-15 | C28H27F3N6O2 | 2793404-47-2 | Details |
| DC-BPi-03 | C14H14N4O2S | 2758411-46-8 | Details |
| p53 Activator 7 | C27H32F3N4OP | 2849340-59-4 | Details |
| Senktide acetate | Details |
| (R)-HH2853 | C31H36F3N7O3 | 2202678-06-4 | Details |
| AXL-IN-13 | C34H41FN6O5 | 2376928-82-2 | Details |
| Endo-1,3-β-glucanase | 9025-37-0 | Details |
| GRGDSPK acetate | 144027-77-0 | Details |
| SRI-42127 | C19H20N6O | 2727872-68-4 | Details |
| hCAII-IN-9 | C15H16ClN3O5S2 | 2878477-18-8 | Details |
| PRMT6-IN-3 | C19H26N4O2S | 2890765-10-1 | Details |
| CZL55 | C20H22N2O6 | 667408-87-9 | Details |
| [Sar1, Ile8]-Angiotensin II 3TFA | C46H73N13O10 | Details |
| RSS0680 | C52H64N10O6S3 | 2769753-48-0 | Details |
| P 218 | C18H25ClN4O4 | 1142407-60-0 | Details |
| Brentuximab | 2088770-90-3 | Details |
| Glembatumumab vedotin | 1182215-65-1 | Details |
| Inotuzumab | 1660159-36-3 | Details |
| RSH-7 | C22H25FN8O | 2764609-97-2 | Details |
| NP10679 | C23H26F3N3O3 | 2914889-88-4 | Details |
| TGFβ1-IN-3 | C23H30N4O5 | 2883813-58-7 | Details |
| Zilovertamab | 1643432-38-5 | Details |
| GW297361 | C16H12N4O3S2 | 388627-21-2 | Details |
| AUTAC1 | C44H63FN8O11S | 2241669-09-8 | Details |
| Larotinib | C24H26ClFN4O4 | 1438072-11-7 | Details |
| Cibisatamab | 1855925-27-7 | Details |
| Sonepcizumab | 1031360-18-5 | Details |
| DATPT | C24H38N6O3.ClH | 2891582-75-3 | Details |
| USP28-IN-3 | C23H20Cl2N2O3S | 2931509-14-5 | Details |
| GSK3-IN-3 | C24H35N3O4 | 331963-27-0 | Details |
| SMN-C2 | C24H27N5O2 | 1446311-56-3 | Details |
| Theralizumab | 906068-56-2 | Details |
| Akt3 degrader 1 | C53H72N8O4 | 2836342-69-7 | Details |
| PU.1-IN-1 | C18H22N2O2S | 873588-27-3 | Details |
| ccc_R08 | C22H19ClO6 | 2919019-72-8 | Details |
| Ordesekimab | 879293-15-9 | Details |
| CpG ODN 10101 | 1234402-77-7 | Details |
| STING agonist-30 | C15H16N4O8 | 2951078-67-2 | Details |
| GSNKGAIIGLM(131602-53-4(free base)) | C45H81N13O14S | Details |
| CLK8 | C29H26N2O6 | 898920-65-5 | Details |
| STC314 | C13H25NaO32S7 | 186295-19-2 | Details |
| ENT-C225 | C26H40N4O5 | 2919962-53-9 | Details |
| TJ08 | C22H16FN3O4 | 2924274-19-9 | Details |
| TGFβ1-IN-2 | C23H30N4O4S | 2700263-58-5 | Details |
| BPDA2 | C24H30O5 | 2907659-86-1 | Details |
| HA5 | C15H10O5 | 2378406-17-6 | Details |
| P-gb-IN-1 | C30H28N2O6 | 2632874-49-6 | Details |
| LSD1-IN-27 | C24H25N3 | 2904571-94-2 | Details |
| Tubulin polymerization-IN-43 | C17H13F4N3O | 2773345-90-5 | Details |
| AP-C2 | C18H16N4S | 682793-07-3 | Details |
| KSK67 | C22H27N3O2 | 2566715-93-1 | Details |
| Antiviral agent 34 | C29H33N3O2S | 945152-88-5 | Details |
| lorvotuzumab | 339306-30-8 | Details |
| HDAC-IN-57 | C21H19N3O4 | 2716217-79-5 | Details |
| 17β-HSD10-IN-1 | C16H13ClN4O3S | 2316765-78-1 | Details |
| Anti-inflammatory agent 51 | C22H22N6O6S | 2911610-03-0 | Details |
| MoTPS1-IN-1 | C23H27F3N2O4 | 2991072-02-5 | Details |
| TV 3279 | C16H20N2O2 | 209394-29-6 | Details |
| Nurr1 agonist 2 | C18H14O3S | 742058-34-0 | Details |
| Z16078526 | C18H17N3O4S | 852222-94-7 | Details |
| LW3 | C17H12F3N3O | 2803367-68-0 | Details |
| TNF-α-IN-9 | C17H14O4 | 2054199-25-4 | Details |
| Clivatuzumab | 1622075-09-5 | Details |
| VU534 | C21H22FN3O3S2 | 923509-20-0 | Details |
| FC-116 | C21H20FNO4 | 2417298-29-2 | Details |
| PLH1215 | 1332084-64-6 | Details |
| 1H-Indole, 3,3'-(2-thienylmethylene)bis[2-methyl- | C23H20N2S | 138801-72-6 | Details |
| SARS-CoV-2-IN-39 | C14H8ClF4NO3 | 2882823-03-0 | Details |
| BCAT-IN-4 | C19H14N2O4S | 406190-85-0 | Details |
| BCPA | C22H22Cl2N2O2 | 547731-67-9 | Details |
| CCG-13514 | C25H25BrN2O2 | 423741-32-6 | Details |
| A2B receptor antagonist 2 hydrochloride | C12H15N5.ClH | 724-70-9 | Details |
| MyD88-IN-1 | C23H24N6O7S | 2911609-80-6 | Details |
| KM02894 | C7H9N3OS2 | 116850-74-9 | Details |
| DJ4 | C19H16N4OS | 1681020-24-5 | Details |
| Enfortumab | 1448664-46-7 | Details |
| Cbl-b-IN-5 | C17H17N5OS | 2368835-59-8 | Details |
| MMP-9-IN-6 | C25H19NO2 | 2241964-36-1 | Details |
| PLH2058 | 2525206-41-9 | Details |
| Topoisomerase II inhibitor 14 | C15H11Cl2N5 | 305343-00-4 | Details |
| Bivatuzumab | 214559-60-1 | Details |
| DSPE-NHS | C49H89N2O13P | 1383932-86-2 | Details |
| JHU 75528 | C23H21Cl2N5O2 | 947696-17-5 | Details |
| Product Total： Product Page： | ||||
| 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 | ||||